This is 12-week, open-label study of abiraterone acetate in at least 50 patients with metastatic castration-resistant prostate cancer. The primary endpoint is total testosterone at pharmacokinetic steady-state. Additional secondary endpoints include safety assessments, PSA and pharmacokinetic measurements